Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 2 November 2026.

Announcements

293

Total raised

£10.5B

disclosed amounts

Other
$5.0M

The new capital will support the creation of eight deep technology startups this year.

"This investment underlines the growing importance of DeepTech startups for the UK’s industrial strategy. CFT is poised for continued expansion, aiming to establish a sister VC arm to further strengthen our venture-building capabilities."
— Owen Thompson, CEO and co-founder
Other

Bowmark Capital has backed Eque2 alongside returning investor WestBridge to support further product development and growth.

"Bowmark are the perfect partners for the next phase of our journey as we look to invest even more in product development and customer support."
— Justin Moule, CEO
Other

Populous makes a strategic investment in event planning software provider OnePlan.

"This investment opens an exciting new chapter for OnePlan, building on the fast growth we’ve experienced to date. The unrivalled knowledge and specialisms of the team at Populous will deepen the positive impact our software provides. We’re excited by the new opportunities this partnership opens, and the many benefits it creates for events and venues across the world."
— Paul Foster, Founder and CEO
Other
€1.5M

The Irish artificial intelligence startup has raised €1.5m led by Elkstone to bring its finance assistant Mary to market.

"With the advent of LLMs, what was once unimaginable is now possible. AI’s capability to ingest and process vast amounts of unstructured data enables us to redefine the boundaries of productivity in the finance department. By taking on tasks that were previously too complex to automate, Mary elevates the role of finance teams and empowers them to engage in higher-value activities that require strategic thinking and creativity."
— David Kearney, Co-founder and CEO
Other
£4.7M

The financing round was led by SCVC with participation from a group of institutional investors and agencies.

"Essentially, our technology generates very small droplets which are ideal for peripheral inhalation drug delivery, and also the potential for systemic drug delivery through the inhalation route rather than via injection."
— Elijah Nazarzadeh